Profile data is unavailable for this security.
About the company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
- Revenue in DKK (TTM)19.76bn
- Net income in DKK4.64bn
- Incorporated1998
- Employees2.64k
- LocationGenmab A/SCarl Jacobsens Vej 30VALBY 2500DenmarkDNK
- Phone+45 70202728
- Fax+45 70202729
- Websitehttps://www.genmab.com/
Mergers & acquisitions
| Acquired company | GMAB:CPH since announced | Transaction value |
|---|---|---|
| ProfoundBio US Co | -30.61% | 1.80bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BACHEM HOLDING AG | 4.62bn | 908.70m | 40.69bn | 2.01k | 44.63 | 3.89 | 31.55 | 8.80 | 1.52 | 1.52 | 7.71 | 17.42 | 0.3585 | 1.06 | 4.33 | 288,020.40 | 7.05 | 8.85 | 8.10 | 10.28 | 31.04 | 31.63 | 19.66 | 19.74 | 1.57 | 100.82 | 0.0002 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Zealand Pharma A/S | 76.87m | -1.05bn | 50.46bn | 298.00 | -- | 5.65 | -- | 656.47 | -16.69 | -16.69 | 1.21 | 125.74 | 0.013 | 3.73 | 0.2625 | 303,834.00 | -17.83 | -42.74 | -18.63 | -50.24 | 72.06 | 96.13 | -1,369.25 | -464.66 | 35.49 | -- | 0.042 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Qiagen NV | 13.91bn | 657.55m | 66.68bn | 5.90k | 100.86 | 2.59 | 31.18 | 4.79 | 0.387 | 0.387 | 8.35 | 15.06 | 0.3229 | 2.03 | 5.71 | 312,538.30 | 1.53 | 5.41 | 1.77 | 6.53 | 62.73 | 64.65 | 4.73 | 16.35 | 1.89 | -- | 0.3523 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Genmab A/S | 19.76bn | 4.64bn | 95.63bn | 2.64k | 20.24 | 2.88 | 32.18 | 4.84 | 71.38 | 71.38 | 303.48 | 502.60 | 0.5277 | 10.98 | 3.37 | 8,966,878.00 | 12.39 | 17.43 | 13.76 | 18.59 | 96.08 | -- | 23.47 | 35.87 | 5.15 | -- | 0.03 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| argenx SE | 13.15bn | -285.10m | 248.16bn | 1.15k | -- | -- | -- | 18.87 | -0.7966 | -0.7966 | 29.00 | -- | -- | -- | -- | 1,535,702.00 | -- | -17.65 | -- | -19.79 | 89.56 | -- | -2.17 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| Lonza Group AG | 53.58bn | 4.58bn | 298.78bn | 17.83k | 65.15 | 3.86 | 32.81 | 5.58 | 7.94 | 7.94 | 92.53 | 133.83 | 0.3767 | 2.60 | 4.35 | 372,000.00 | 3.23 | 5.07 | 3.81 | 6.21 | 29.21 | 39.15 | 8.57 | 14.52 | 1.38 | 5.14 | 0.2873 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 29 Dec 2023 | 3.24m | 4.89% |
| Schroder Investment Management Ltd.as of 31 Aug 2024 | 2.28m | 3.45% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 2.23m | 3.37% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.43m | 2.16% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 1.17m | 1.76% |
| Baillie Gifford & Co.as of 31 Oct 2024 | 902.48k | 1.36% |
| Amundi Asset Management SA (Investment Management)as of 13 Nov 2024 | 678.05k | 1.03% |
| Geode Capital Management LLCas of 14 Nov 2024 | 647.10k | 0.98% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 615.00k | 0.93% |
| Harding Loevner LPas of 30 Sep 2024 | 591.34k | 0.89% |
